Vilon (KE): Research Overview
The shortest Khavinson bioregulator — two amino acids — studied in immune and ageing research.
Also known as KE · Lys-Glu
What is Vilon?
Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, originally isolated from thymus gland extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it acts as a molecular signaling compound that restores normal gene expression and protein synthesis in immune and epithelial cells.
What is Vilon researched for?
- Stimulates thymocyte proliferation and enlarges thymic lobules.
- Activates T-helper cells and improves immune response.
- Restores chromatin structure and gene expression in aged lymphocytes.
- Long-term treatment increased mean lifespan 20-40% in rodent studies.
- Suppresses development of spontaneous and induced tumors.
- Promotes recovery in tissues exposed to radiation damage.
- Restores brush border membrane enzyme levels in aged animals.
- Enhances intestinal barrier function in aged rats.
How does Vilon work?
Vilon works through epigenetic modulation, restoring chromatin structure and gene expression in immune cells. It stimulates thymocyte proliferation, activates T-helper cells, and increases the proliferative index in thymus tissue (from 26% to 37% in studies).
References
Peptide Bioregulators Increase Lifespan
Biogerontology · 2003
Long-term treatment with peptide preparations including Vilon increased mean lifespan 20-40% and suppressed tumorigenesis.
Vilon Effects on Aged Lymphocytes
Bulletin of Experimental Biology and Medicine · 2002
Vilon improved lymphocytes from old people by restoring chromatin structure and gene expression.
Peptides Regulating Proliferative Activity in THP-1
Cells PMC · 2022
Vilon and other Khavinson peptides modulate key proliferative patterns and tyrosine phosphorylation of kinases.
Short Peptide Immunoprotecting Properties
Advances in Gerontology · 2018
Vilon and related peptides possess age-associated immunoprotecting properties in the spleen.
Common questions
How significant is the 20-40% lifespan extension from Vilon - is it proven in humans?
Animal studies showed 20-40% mean lifespan increases with long-term Vilon treatment plus tumor suppression. These are compelling preclinical findings but haven't been replicated in human longevity trials - lifespan extension is theorized based on mechanisms and animal models rather than clinical proof. Effects in humans are likely more modest.
Is Vilon the shortest bioregulator peptide and does size matter for absorption?
Yes, Vilon is the shortest Khavinson peptide at just 2 amino acids, giving it excellent oral absorption. The dipeptide size allows convenient capsule administration with good GI bioavailability - making it more practical than longer peptide bioregulators requiring injection.